Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
|
US |
|
M
|
Molibdenos y Metales SA
SGO:MOLYMET
|
CL |
|
Isgec Heavy Engineering Ltd
NSE:ISGEC
|
IN |
|
Appotronics Corp Ltd
SSE:688007
|
CN |
|
HCR Co Ltd
SSE:688500
|
CN |
|
N
|
New Century Group Hong Kong Ltd
HKEX:234
|
HK |
|
S
|
Solstad Maritime ASA
OSE:SOMA
|
NO |
|
S
|
Shandong Boan Biotechnology Co Ltd
HKEX:6955
|
CN |
|
S
|
S Kijchai Enterprise PCL
SET:SKN
|
TH |
|
A
|
Anbang Save-Guard Group Co Ltd
SSE:603373
|
CN |
|
C
|
Corporacion Interamericana de Entretenimiento SAB de CV
BMV:CIEB
|
MX |
|
Beijing Trust & Far Technology Co Ltd
SZSE:300231
|
CN |
Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey and currently employs 77 full-time employees. The company went IPO on 2019-10-25. The Company’s pipeline product candidate, vonoprazan is an oral small molecule potassium-competitive acid blocker (P-CAB). P-CABs are a class of medicines that block acid secretion in the stomach. Vonoprazan has an anti-secretory effect and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease (GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey and currently employs 77 full-time employees. The company went IPO on 2019-10-25. The Company’s pipeline product candidate, vonoprazan is an oral small molecule potassium-competitive acid blocker (P-CAB). P-CABs are a class of medicines that block acid secretion in the stomach. Vonoprazan has an anti-secretory effect and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease (GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
Revenue Beat: Full-year 2025 revenue was $175.1 million, at the high end of guidance and up 217% year-over-year.
Profitability Path: Management reiterated expectations to achieve operating profitability in Q3 2026 and cash flow positivity in 2027.
Expense Discipline: Q4 cash operating expenses fell to $50.3 million, nearly 50% lower than earlier in 2025 and below guidance.
Capital Structure: The company improved its balance sheet by extending loan maturities to 2029 and lowering interest rates from 12% to 9.85%.
2026 Guidance: Revenue guidance for 2026 is $320–345 million, reflecting solid growth and an accounting classification change.
Sales Force Momentum: The sales team is nearly at full strength, driving increased physician adoption and prescription volumes.
Market Penetration: Over 1.1 million VOQUEZNA prescriptions have been filled to more than 230,000 patients, with strong GI adoption trends.
